Smith Drug's Exit: A Century-Old Distributor Winds Down

After spending the better part of the last 20 years in the wholesale distribution space, I've been getting many questions about Smith Drug's exit from the market. 

Smith Drug Company, a South Carolina-based wholesale pharmaceutical distributor and century-old division of J.M. Smith Corporation, announced in late July 2026 that it is winding down operations and pursuing the sale of its assets to a strategic buyer or buyers. The transition, which the company says it hopes to complete without a piecemeal liquidation, will affect facilities in Spartanburg, South Carolina; Milton, Vermont; and Paragould, Arkansas, with the company expecting the process to be completed in early 2027.

This is a very layered and complicated issue that I will discuss in very general terms. Rather than focus on how it happened, I want to share what I believe the impact on stakeholders within the market will be going forward. 

Impact on the Industry

Wholesalers – There are very few regional wholesalers anymore, and I don’t think there are any in the local area who can pick up the customers who need to transition. That being said, the “Big-3” do a fantastic job servicing customers. The pharmacies who have traditionally avoided working with one of the Big-3 may be pleasantly surprised by the level of service and support being provided today. Also, pharmacies may have an ability to negotiate as the three compete to capture customers quickly.

Manufacturers – Conceptually, this isn’t great for manufacturers as it’s one less customer. In real terms, they were already part of a buying group and their volume of purchases does not really impact things overall.  It will be interesting to see if there is a sale, or if another secondary wholesaler is able to capture some of Smith Drug’s customer volume.  There is an opportunity for a secondary wholesaler to quickly expand if they are able to provide support.

Customers - The pharmacies who maintained Smith Drug as their primary will have some level of disruption. They now need to find a new primary supplier, and transition NDCs to the new supplier’s primary SKUs, managing all the downstream impact on their patients. In addition, there may be a noticeable change in the contract terms and their ability to manage their own economics. Generally, the higher the compliance that a pharmacy provides to their primary wholesaler, the better their pricing will be. Adopting new primary agreements may limit a pharmacy’s ability to source generic dollars in the secondary market. With all of the direct to provider activity happening now in the institutional space, there may be an opportunity for manufacturers to try a similar approach with impacted pharmacies if they want to maintain their NDC usage.

Retail Buying Groups – This could be a significant opportunity for the current buying groups to step in and provide a solution to the impacted pharmacies. While many of the pharmacies may be a part of a group, there are several that have strong ties to their primary wholesaler and pre-negotiated agreements based upon their scale.

A Door Closes, Another Opens

It’s unfortunate that a company with the legacy of Smith Drug will no longer serve the industry, but with every door that closes, another one opens. I am hopeful that their customers, suppliers, and legacy competitors take this opportunity to review their current business operations to turn this negative into a positive.